Eliminating hepatitis C virus (HCV) in Australia is now a possibility.
Join us for the official launch of Burnet Institute’s Eliminate Hep C Program and hear from leading HCV experts about how elimination could be achieved.
Burnet’s program will address some key global priorities and build upon groundbreaking biomedical research, modelling and analysis that demonstrates the feasibility and public health benefit of eliminating hepatitis C.
HCV affects more than 250,000 Australians resulting in up to 630 deaths from liver cancer and liver failure each year. Globally, more than 500,000 people die from HCV-related causes each year.
Guest speakers will include Burnet Institute’s leading HCV researchers and clinicians, collaborating partners, government, and members of the community and affected populations.
- Professor Margaret Hellard, Burnet Institute, The Hep C landscape
- Professor Greg Dore, Kirby Institute, Access to DAA therapy in Australia
- Dr Joe Doyle, Burnet Institute and Alfred Health, The TAP, Prime and EC Studies
- Professor Alex Thompson, St Vincent’s Hospital, Hep C management in Victorian prisons
- Ms Jenny Kelsall, Harm Reduction Victoria, Hep C in Harm Reduction
- Associate Professor Heidi Drummer, Burnet Institute, Development of a HCV vaccine
- Ms Melanie Eagle, Hepatitis Victoria, Community engagement: Mobilisation for elimination
- Ms Louise Galloway, Victorian Department of Heath and Human Services, Overview of state-level strategy in hepatitis C elimination
- Ms Lia Burns, Burnet Institute, Hepatitis C and harm reduction in Myanmar
- Professor Robert Power, Burnet Institute, Welcome Address
- Professor David Wilson, Burnet Institute, Is elimination of hepatitis C achievable in Australia?
- Judy Jackson, HepCSpeak, A personal story of treatment and cure
- Dr Brett Sutton, Medical Registrar, Burnet Institute, HepCHelp: Helping GPs navigate hep C care